This week in Nephrology
Nov 18, 2026
Finerenone in Patients with Focal Segmental Glomerulosclerosis.
In 215 FIND-CKD participants with FSGS, finerenone slowed eGFR decline by 1.3 ml/min per year and lowered proteinuria about 41 percent, though the hard kidney composite was not significant.
Journal of the American Society of Nephrology · 2026 · PubMed
This week’s highlights
Read the weekly briefing
This AudioScholar briefing is generated by artificial intelligence from PubMed abstracts for healthcare professionals and is not medical advice.
This week: finerenone slows kidney function loss in focal segmental glomerulosclerosis, a year of complement blockade in C3 glomerulopathy holds its gains, and a large veterans analysis compares second blood pressure drugs added to renin-angiotensin blockade.
Welcome to This Week in Nephrology. We're covering 10 papers this week: 3 in depth, 4 in brief, 3 quick signals.
In the Journal of the American Society of Nephrology, Heerspink and colleagues report a prespecified analysis of the FIND-CKD trial in participants with focal segmental glomerulosclerosis [1]. FIND-CKD randomized 1584 adults with nondiabetic chronic kidney disease on stable renin-angiotensin inhibition to finerenone or placebo. Of these, 215 participants had FSGS, split evenly between primary and secondary forms, with a mean eGFR of 45 and heavy proteinuria. Finerenone slowed the total eGFR slope by 1.3 millilitres per minute per year compared with placebo, a statistically significant difference. The effect held among participants with biopsy-proven disease and was similar in primary and secondary FSGS. At one year, proteinuria was about 41 percent lower than with placebo, and participants on finerenone had close to seven times the odds of reaching a protein-to-creatinine ratio below 700 milligrams per gram. The hard kidney composite of major eGFR decline or kidney failure trended lower but was not statistically significant. Hyperkalemia-related events occurred in 15 percent of the finerenone group and 20 percent of the placebo group. The main limitation is that this is a subgroup of a trial not designed for FSGS, so it lacks the power to test hard outcomes. It adds randomized evidence for mineralocorticoid receptor antagonism in a disease with few proven treatments.
Also in the Journal of the American Society of Nephrology, Nester and colleagues report the open-label year of VALIANT, the phase 3 trial of pegcetacoplan, a C3 and C3b inhibitor, in patients aged 12 and over with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis [2]. After 26 weeks of randomized treatment, with 63 participants on pegcetacoplan and 61 on placebo, everyone received the drug for another 26 weeks, and 114 participants completed that period. Participants who stayed on pegcetacoplan kept a proteinuria reduction of about two thirds at one year. Participants switched from placebo saw essentially no change during the placebo phase, then a drop in proteinuria of just over half once they started the drug. The placebo group had lost about 8 units of eGFR during the placebo phase, while a post hoc analysis of a full year of pegcetacoplan across 118 participants showed eGFR essentially unchanged. There were no meningococcal infections, deaths or allograft losses. The limitations are the open-label design, exploratory endpoints, several post hoc comparisons, and one year of follow-up in diseases that progress over many years. It adds durability data to the randomized result, while long-term kidney survival remains untested.
A third paper in the Journal of the American Society of Nephrology, from Gregg and colleagues, takes on a question guidelines leave open: which second antihypertensive to add to an ACE inhibitor or angiotensin receptor blocker in chronic kidney disease [3]. This target trial emulation used Veterans Health Administration data from 2010 to 2016 on 150,369 adults with non-dialysis chronic kidney disease who started a thiazide diuretic, loop diuretic, calcium channel blocker or beta-blocker. Over a median follow-up of about three and a half years, and compared with thiazides, cardiovascular event risk was about a fifth higher with calcium channel blockers, more than half higher with beta-blockers, and roughly double with loop diuretics. The kidney composite of dialysis, transplantation or sustained creatinine doubling was about 40 percent higher with calcium channel blockers, modestly higher with beta-blockers, and roughly double with loop diuretics. The most important limitation is confounding by indication: the groups differed at baseline, and patients started on loop diuretics more often had advanced kidney disease or heart failure. It adds the largest comparative dataset on this question, though no randomized trial has tested it, and the authors frame thiazides as associated with more favourable outcomes.
Now, four in brief.
Returning to focal segmental glomerulosclerosis, Lafargue and colleagues in the American Journal of Transplantation report a retrospective TANGO Consortium study across 23 international centres [4]. Among 136 transplant recipients with biopsy-proven primary FSGS and stored pre-transplant serum, anti-nephrin antibodies were found in 11 patients, about 8 percent. Antibody-positive patients were much younger at diagnosis, with a median age of 7. Their recurrence rate after transplantation was 73 percent against 38 percent in antibody-negative patients, about two and a half times the risk, and recurrence came at a median of one month. Allograft failure did not differ significantly. With only 11 antibody-positive patients in a brief communication, this identifies a subgroup for further study rather than a validated test.
In Kidney International, Fischman and colleagues pooled 3418 Black participants with APOL1 genotyping from the CRIC and SPRINT studies [5]. Compared with other first-line antihypertensives, renin-angiotensin inhibitor use was associated with roughly a third to 40 percent lower risk of the kidney outcome, and the benefit was similar with zero, one or two APOL1 risk alleles. The association was driven by albuminuric participants. Among two-allele carriers, estimates looked similar regardless of albuminuria, though the non-albuminuric estimate was imprecise. Like the veterans analysis, this is observational evidence on drug choice, and the authors call for further studies given small subgroups and confounding in prescribing.
In Nephrology Dialysis Transplantation, Hussain and colleagues compared a minimal-steroid regimen with avacopan against standard high-dose steroids in ANCA-associated vasculitis [6]. In this two-centre retrospective cohort of 126 patients, the avacopan regimen used prednisolone for only two weeks and cut cumulative steroid exposure by about 90 percent. Sustained remission at 12 months was above 90 percent in both groups, with no significant differences in relapse, eGFR recovery or severe infection. Patient-reported symptom burden was significantly lower with avacopan. The authors describe the findings as supportive of feasibility rather than confirmatory.
On the same disease, Milon and colleagues in the American Journal of Kidney Diseases followed 460 adults with ANCA-associated vasculitis and kidney involvement across 7 French centres for a median of about five years [7]. Major relapse occurred in 23 percent of patients, with a 10-year cumulative incidence of 31 percent. The majority of relapse events involved the kidney, and relapse was associated with roughly four times the risk of kidney failure, but not with death. Existing relapse scores discriminated poorly, and the best new model was only moderate. The design is retrospective, with treatment practices changing over two decades.
Three quick signals.
In the American Journal of Kidney Diseases, Heerspink and colleagues report a National Kidney Foundation workshop concluding that urinary albumin is generally preferred over total protein for clinical practice and trials [8]. The reasons given are international assay standardization expected from 2027, better documented sample handling, and a moderately stronger link with outcomes. This is a consensus report, with no new data.
In Kidney International Reports, Stoneman and colleagues followed 1382 adults with IgA nephropathy in British Columbia over 21 years [9]. The 20-year risk of kidney failure approached 50 to 60 percent across age groups, but stayed below 10 percent with low proteinuria and preserved eGFR. The International IgAN Prediction Tool tracked long-term risk. This is a single-province observational cohort.
Also in the American Journal of Kidney Diseases, Teixeira and colleagues review continuous kidney replacement therapy in patients on mechanical circulatory support, where acute kidney injury affects up to 85 percent of patients [10]. They cover access, circuit integration and anticoagulation. This is a narrative practical review rather than new evidence.
Stepping back across this week's papers, the glomerular disease trials rest on proteinuria and eGFR slope, while their hard kidney outcomes remain underpowered or untested. Where trials are absent, as in choosing a second antihypertensive or reducing steroids in vasculitis, large observational cohorts and retrospective series are filling the gap, and each carries the confounding of how treatment was chosen. Several prognostic tools also discriminate only modestly, leaving risk prediction in glomerular disease incomplete.
If you only have time for one paper this week, make it the finerenone analysis in focal segmental glomerulosclerosis [1]. It is randomized evidence that reopens whether mineralocorticoid receptor antagonism belongs alongside renin-angiotensin blockade in a glomerular disease with few proven therapies.
That's your roundup for This Week in Nephrology. The full transcript and references are available on the episode page. See you next week.
If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And think of one colleague, in any specialty, who never has time to keep up with the literature. Tell them about AudioScholar: a ten-minute weekly for every specialty, to listen to in any podcast app, or to read at audioscholar dot C C.
This is an automated summary generated by artificial intelligence, which can make mistakes. Use it to choose which papers to read in full.
Get Nephrology every week
By email, Spotify, Apple or any podcast app.
Spot something worth flagging?